Articles from Radicle Science

Backed by Resilience Capital and invited into elite accelerator cohorts including One Mind and Plug & Play, Radicle Science is scaling a new standard for evidence-based innovation for consumer health products.

Radicle Science, a transformative healthtech B-corp validating health and wellness products for the first time, will launch history’s first large-scale, blinded, placebo-controlled clinical trials on rare cannabinoids including THCV, CBN, CBG, and CBC, to study their effects on energy, focus, appetite, sleep disturbance, pain, stress, and anxiety. These unprecedented Radicle Discovery studies will involve more than 10,000 participants and are set to kick off in early 2022.

Radicle Science, a transformative healthtech B-corp validating natural products for the first time, announces initial findings from the Radicle ACES (Advancing CBD Education and Science) study–history’s largest longitudinal real world evidence (RWE) study of nearly 3,000 participants to determine effectiveness of botanical products containing CBD.

Radicle Science, a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021.

Radicle Science, a transformative healthtech B-corp validating natural products for the first time, and Open Book Extracts (OBX), a leading ingredient manufacturer and product developer of cannabinoid-enabled products, announce the launch of an alliance to advance the development of market-leading, scientifically validated CBD and cannabinoid products.

Radicle Science, a transformative healthtech B-corp validating natural products for the first time, announces the launch of the Radicle ACES (Advancing CBD Education and Science) study.